First patient in treatment in RhoVac's clinical phase IIb study in the USA

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

First patient in treatment in RhoVac's clinical phase IIb study in the USA

RhoVac AB ("RhoVac") announces today, August 10th 2020, that the first patient in the USA is included in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac").

PR Newswire

STOCKHOLM, Aug. 10, 2020 /PRNewswire/ -- The first patient in the USA is included in RhoVac's clinical phase IIb study, called BRaVac. The first US clinic to include a patient in the study was Carolina Urologic Research Center. BraVac is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. BRaVac is an international, multi-centre study, which will recruit over 175 patients in six European countries (Denmark, Finland, Germany, Belgium, Sweden, and the UK) plus the USA. The study has already commenced in Denmark, Finland, Germany, Belgium and now in the USA. RhoVac anticipates recruitment to start very soon also in Sweden and the UK, and the company expects the phase IIb recruitment to be complete by end 2020, and the trial to conclude end 2021.

Anders Månsson, CEO, comments: "We have truly reached a great milestone in now recruiting patients also in the USA, which is the largest and most important market in the world for our drug candidate RV001. I am very happy and proud that we have been able to keep our important clinical phase IIb trial going, and that more and more countries are joining the study, despite the impact of the pandemic."

For further information, please contact:

Anders Månsson - CEO, RhoVac AB
Phone number: +46 73-751 72 78

This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 10th August 2020.

This information was brought to you by Cision,c3166141

The following files are available for download:


Cision View original content:


Copyright CNW Group 2020

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).